CollPlant Biotechnologies
CLGN
15 hedge funds and large institutions have $17M invested in CollPlant Biotechnologies in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
150% more funds holding
Funds holding: 6 → 15 (+9)
66% more capital invested
Capital invested by funds: $10.2M → $17M (+$6.79M)
3.6% more ownership
Funds ownership: 14.69% → 18.28% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FA
Friess Associates
Greenville,
Delaware
|
+$3.77M |
| 2 |
IMOV
Investment Management of Virginia
Richmond,
Virginia
|
+$3.7M |
| 3 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$2.33M |
| 4 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$834K |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$824K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$126K |
CLGN Hedge Fund Activity: Q1 2021 in Review
15 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q1 2021, worth a combined $17M — up 66% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLGN positions and 1 closed out — a net gain of 9 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Friess Associates, opening a new position worth an estimated $3.77M. The largest seller was Citadel Advisors, exiting entirely with an estimated $126K sold.
- 15 institutional investors held CollPlant Biotechnologies (CLGN) as of Q1 2021, up from 6 in Q4 2020.
- Funds reported $17M of CollPlant Biotechnologies stock for Q1 2021, up 66% quarter-over-quarter.
- 10 funds opened new CollPlant Biotechnologies positions in Q1 2021 and 1 closed out, a net change of +9 holders.
- The largest CollPlant Biotechnologies buyer in Q1 2021 was Friess Associates, an estimated $3.77M added.
- The largest CollPlant Biotechnologies seller in Q1 2021 was Citadel Advisors, an estimated $126K sold.
Based on aggregated 13F filings for Q1 2021.